NanoCarrier Co., Ltd. (4571) AI Stock Analysis

• Market Cap: ¥12.96B
• Dividend Yield: N/A
• Average Volume (3M): 2.35M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.81
• Revenue Growth: 172.39%
• EPS Growth: 8.27%
• Country: JP
• Employees: 18
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -2.86
• Shares Outstanding: 75,374,160
• 10 Day Avg. Volume: 484,410
• 30 Day Avg. Volume: 2,345,523
• PEG Ratio: -1.80
• Price to Book (P/B): 3.71
• Price to Sales (P/S): 93.58
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: ¥167.00 ▲(24.63% Upside)
• Action: Upgraded Date: 02/28/26
• Date: Action: Upgraded 02/28/26

The score is held back primarily by weak financial performance (shrinking revenue, large ongoing losses, and continued cash burn). Technical momentum is a meaningful offset with the stock trading above major moving averages and positive MACD, while valuation remains constrained by negative earnings and no dividend.

Positive Factors

High gross margins

Sustained gross margins around 72% indicate the core DDS formulations have high incremental profitability. Over the medium term this supports attractive economics for licensing or contract work: most incremental revenue converts to gross profit, improving partner negotiation leverage and margin resilience as scale grows.

Manageable leverage

Low leverage and reduced absolute debt provide financial flexibility during long development cycles. A modest debt burden lowers fixed financing costs and preserves capacity to raise equity or secure partner-backed funding, which is important for sustaining R&D without onerous interest pressure.

Platform licensing business model

A platform-focused DDS model generates revenue via upfronts, milestones, and services, offering asymmetric upside when partners advance programs. Structural reliance on partnerships lets the company monetize IP without full commercialization costs, creating durable optionality if it secures meaningful collaborations.

Negative Factors

Persistent cash burn

Consistent negative operating cash flow shows the company cannot self-fund development and must rely on financing or partners. Over months this increases dilution or refinancing risk, constrains runway for clinical programs, and makes long-term planning dependent on external capital timing.

Shrinking revenue base

A multi-year revenue decline undermines scale and operating leverage, making fixed R&D and G&A disproportionately costly. Structurally weaker top-line reduces bargaining power with partners, limits reinvestment capacity, and raises the bar for reaching sustainable margins without new agreements.

Large losses and equity erosion

Very large net losses and negative ROE are eroding the capital base, increasing the likelihood of future equity raises and dilution. Over the medium term this weakens balance-sheet credibility, complicates fundraising terms, and can delay or dilute the economics of future licensing or commercialization outcomes.

NanoCarrier Co., Ltd. Business Overview & Revenue Model

Company Description

NANO MRNA Co., Ltd. engages in the research, development, and production of pharmaceuticals using micellar nanoparticles technology. The company develops biopharmaceutical products focused on the medication of cancer and other intractable diseases. It also engages in the research, development, manufacture, and sale of anti-cancer drugs based on micellar nanoparticle technology. The company was founded by Kazunori Kataoka, Teruo Okano, and Ichiro Nakatomi on June 14, 1996 and is headquartered in Tokyo, Japan.

How the Company Makes Money

NanoCarrier’s earnings are primarily tied to monetizing its drug delivery platform and related development pipeline through partnering and R&D-related receipts. Key revenue streams typically include (1) collaboration and licensing income from granting partners rights to use its DDS technology and/or specific drug candidates (e.g., upfront payments and contractually defined milestone payments tied to development, regulatory, and commercialization progress), and (2) research and development services/contract revenue associated with conducting agreed development activities for partners under collaboration arrangements. Royalties on sales of partnered products, if any products reach commercialization under license, would be an additional revenue stream; however, specific details on current royalty-bearing products or active commercialization-based revenue are null. The company’s ability to generate revenue is therefore driven by its ability to secure and maintain strategic partnerships, progress its pipeline to value-inflection milestones (such as clinical trial advancement and regulatory submissions), and negotiate favorable licensing terms; specific named partnerships and the exact composition of revenue by stream are null.

NanoCarrier Co., Ltd. Financial Statement Overview

Summary

Overall financial quality is weak: revenue has been shrinking, losses remain very large, and cash flow is consistently negative. The balance sheet leverage is modest and improving (lower debt-to-equity), but ongoing losses and cash burn continue to erode equity and dominate the risk profile.

Income Statement

Revenue has been shrinking for several years (down again in FY2025), which is a clear negative for scale and operating leverage. While gross margin remains very high (~72% in FY2025), the company continues to post very large operating and net losses (FY2025 net margin roughly -770%), indicating that operating expenses and R&D spend are far above the current revenue base. Losses have improved versus the worst year (FY2022–FY2023), but profitability remains structurally weak and visibility to breakeven appears limited based on the provided trend.

Balance Sheet

Leverage looks manageable with debt-to-equity around 0.20 in FY2025 and total debt reduced materially versus FY2024, which supports financial flexibility. However, equity has been declining over time, consistent with repeated net losses, and returns on equity remain deeply negative (about -30% in FY2025). Overall, the balance sheet is not highly levered, but ongoing losses are eroding the capital base and remain the key risk.

Cash Flow

Cash generation is weak: operating cash flow is negative across all reported years and was still meaningfully negative in FY2025, implying continued cash burn to fund operations. Free cash flow has been negative historically (notably FY2022–FY2024), and the business has not demonstrated a sustained ability to self-fund, increasing reliance on financing or existing liquidity. The pace of burn has improved from earlier years, but remains a material overhang.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	116.22M	108.52M	135.51M	202.19M	264.03M	313.26M
Gross Profit	84.46M	78.17M	110.96M	159.60M	220.88M	274.88M
EBITDA	-755.92M	-755.33M	-863.31M	-1.25B	-2.06B	-1.30B
Net Income	-880.20M	-835.38M	-780.00M	-1.31B	-1.88B	-2.84B
Balance Sheet
Total Assets	3.93B	4.00B	5.07B	5.78B	7.14B	7.82B
Cash, Cash Equivalents and Short-Term Investments	3.40B	3.51B	4.28B	4.44B	5.95B	6.40B
Total Debt	540.24M	540.24M	1.11B	1.11B	1.15B	0.00
Total Liabilities	1.28B	1.26B	1.65B	1.53B	1.57B	321.00M
Stockholders Equity	2.66B	2.74B	3.42B	4.25B	5.57B	7.50B
Cash Flow
Free Cash Flow	0.00	0.00	-585.08M	-1.09B	-1.76B	-1.25B
Operating Cash Flow	0.00	-401.62M	-585.08M	-1.09B	-1.75B	-1.25B
Investing Cash Flow	0.00	587.53M	793.01M	1.21B	-244.13M	-871.69M
Financing Cash Flow	0.00	-568.77M	3.73M	32.20M	1.15B	-11.46M

NanoCarrier Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 134.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4571, the sentiment is Positive. The current price of 134 is below the 20-day moving average (MA) of 175.05, below the 50-day MA of 156.84, and below the 200-day MA of 149.43, indicating a neutral trend. The MACD of 3.64 indicates Positive momentum. The RSI at 53.41 is Neutral, neither overbought nor oversold. The STOCH value of 40.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4571.

NanoCarrier Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4888	62 Neutral	¥19.06B	-8.45	―	―	248.15%	76.92%
4588	55 Neutral	¥69.89B	-17.30	―	―	-9.04%	13.09%
4571	52 Neutral	¥12.96B	-12.44	-26.70%	―	172.39%	8.27%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4563	47 Neutral	¥22.55B	-18.88	-184.71%	―	56.75%	-97.56%
4583	47 Neutral	¥7.94B	-7.39	―	―	25.28%	39.15%
4564	42 Neutral	¥8.82B	-7.89	-63.25%	―	99.87%	40.60%

NanoCarrier Co., Ltd. Corporate Events

Nano Holdings Begins First-in-Human mRNA Trial Targeting Knee Osteoarthritis

Nano Holdings, Inc., a Japan-based healthcare value creation platform, focuses on advancing Japanese-origin biomedical technologies to global markets by aligning scientific innovation with international business expertise. The company leverages cross-border collaboration to develop and scale novel therapeutic platforms, aiming to enhance its presence in the global healthcare and biotech ecosystem.

Nano Holdings announced that the first patient has been dosed in a Phase 1 first-in-human trial of its RUNX1 mRNA therapy for knee osteoarthritis, conducted in Australia through its local subsidiary PrimRNA AU Pty Ltd. The trial, the world’s first intra-articular mRNA therapeutic injection into the knee for osteoarthritis, underscores a strategic Australia–Japan collaboration and could position the company at the forefront of disease-modifying regenerative treatments in a large, underserved osteoarthritis market.

RUNX1 mRNA is designed to activate regenerative pathways within cartilage and directly target the underlying disease mechanisms in osteoarthritis rather than just alleviating symptoms. If successful, this approach could eventually offer an alternative to current symptomatic therapies such as NSAIDs, steroid or hyaluronic acid injections, and may delay or reduce the need for total joint replacement surgery in knee osteoarthritis patients.

The most recent analyst rating on (JP:4571) stock is a Hold with a Yen181.00 price target. To see the full list of analyst forecasts on NanoCarrier Co., Ltd. stock, see the JP:4571 Stock Forecast page.